J Q Chen1, Y Bao1, J Lee2, J L Murray3, J K Litton3, L Xiao4, R Zhou5, Y Wu6, X Y Shen7, H Zhang6, A A Sahin6, R L Katz6, M L Bondy5, N L Berinstein8, G N Hortobagyi3, L G Radvanyi9. 1. Departments of Breast Medical Oncology; Melanoma Medical Oncology. 2. Systems Biology. 3. Departments of Breast Medical Oncology. 4. Pathology, UT MD Anderson Cancer Center, Houston, USA; Department of Pathology, Shanghai Huadong Hospital, Shanghai, China. 5. Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston. 6. Pathology, UT MD Anderson Cancer Center, Houston, USA. 7. Department of Pathology, Veterans Administration Hospital, Baylor College of Medicine, Houston, USA. 8. Sunnybrook Health Sciences Center, Toronto, Canada. 9. Departments of Breast Medical Oncology; Melanoma Medical Oncology. Electronic address: lradvanyi@mdanderson.org.
Abstract
BACKGROUND: TRPS-1 is a new GATA transcription factor that is differentially expressed in breast cancer (BC) where it been found recently to regulate epithelial-to-mesenchymal transition (EMT). PATIENTS AND METHODS: We carried out a quantitative immunohistochemistry (qIHC) analysis of TRPS-1 expression in 341 primary-stage I-III BC samples in relation to patient clinical characteristics as well as its prognostic value, especially in an estrogen receptor-positive (ER+) subgroup. RESULTS: Higher TRPS-1 expression was significantly associated with a number of clinical and pathological characteristics as well as with improved overall survival (OS) and disease-free survival (DFS). Among stage I/II ER+ BC patients who received endocrine therapy alone, those with high TRPS-1 expression had significantly longer OS and DFS. There was also a strong association between TRPS-1 levels and the EMT marker E-cadherin in the ER+ invasive ductal carcinoma cases. Analysis of gene expression data on a panel of BC lines found that TRPS-1 expression was low or absent in BC lines having enriched mesenchymal features. CONCLUSIONS: Our data indicated that TRPS-1 is an independent prognostic marker in early-stage BC and a new EMT marker that can distinguish patients with ER+ BC who will respond longer to adjuvant endocrine therapy.
BACKGROUND:TRPS-1 is a new GATA transcription factor that is differentially expressed in breast cancer (BC) where it been found recently to regulate epithelial-to-mesenchymal transition (EMT). PATIENTS AND METHODS: We carried out a quantitative immunohistochemistry (qIHC) analysis of TRPS-1 expression in 341 primary-stage I-III BC samples in relation to patient clinical characteristics as well as its prognostic value, especially in an estrogen receptor-positive (ER+) subgroup. RESULTS: Higher TRPS-1 expression was significantly associated with a number of clinical and pathological characteristics as well as with improved overall survival (OS) and disease-free survival (DFS). Among stage I/II ER+ BC patients who received endocrine therapy alone, those with high TRPS-1 expression had significantly longer OS and DFS. There was also a strong association between TRPS-1 levels and the EMT marker E-cadherin in the ER+ invasive ductal carcinoma cases. Analysis of gene expression data on a panel of BC lines found that TRPS-1 expression was low or absent in BC lines having enriched mesenchymal features. CONCLUSIONS: Our data indicated that TRPS-1 is an independent prognostic marker in early-stage BC and a new EMT marker that can distinguish patients with ER+ BC who will respond longer to adjuvant endocrine therapy.
Entities:
Keywords:
TRPS-1; breast cancer; immunohistochemistry; prognostic marker
Authors: Marie-Liesse Asselin-Labat; Kate D Sutherland; Holly Barker; Richard Thomas; Mark Shackleton; Natasha C Forrest; Lynne Hartley; Lorraine Robb; Frank G Grosveld; Jacqueline van der Wees; Geoffrey J Lindeman; Jane E Visvader Journal: Nat Cell Biol Date: 2006-12-24 Impact factor: 28.824
Authors: Laszlo Radvanyi; Devender Singh-Sandhu; Scott Gallichan; Corey Lovitt; Artur Pedyczak; Gustavo Mallo; Kurt Gish; Kevin Kwok; Wedad Hanna; Judith Zubovits; Jane Armes; Deon Venter; Jalil Hakimi; Jean Shortreed; Melinda Donovan; Mark Parrington; Pamela Dunn; Ray Oomen; James Tartaglia; Neil L Berinstein Journal: Proc Natl Acad Sci U S A Date: 2005-07-25 Impact factor: 11.205
Authors: André Albergaria; Joana Paredes; Bárbara Sousa; Fernanda Milanezi; Vítor Carneiro; Joana Bastos; Sandra Costa; Daniella Vieira; Nair Lopes; Eric W Lam; Nuno Lunet; Fernando Schmitt Journal: Breast Cancer Res Date: 2009-06-23 Impact factor: 6.466
Authors: Roberto Rangel; Song-Choon Lee; Kenneth Hon-Kim Ban; Liliana Guzman-Rojas; Michael B Mann; Justin Y Newberg; Takahiro Kodama; Leslie A McNoe; Luxmanan Selvanesan; Jerrold M Ward; Alistair G Rust; Kuan-Yew Chin; Michael A Black; Nancy A Jenkins; Neal G Copeland Journal: Proc Natl Acad Sci U S A Date: 2016-11-14 Impact factor: 11.205
Authors: Batzaya Davaadelger; Alina R Murphy; Susan E Clare; Oukseub Lee; Seema A Khan; J Julie Kim Journal: Endocrinology Date: 2018-10-01 Impact factor: 4.736